

**Table SII. Determinants of overall cyclosporine A survival by reasons of treatment discontinuation**

	Failure			Side-effects			Remission		
	OR	CI	p-value	OR	CI	p-value	OR	CI	p-value
Age of onset of CsA treatment									
0–18 years	1.23	0.30–4.24	0.76	0.44	0.06–1.81	0.31	0.48	0.13–1.53	0.22
19–40 years	0.95	0.33–2.88	0.93	0.95	0.33–2.88	0.93	1.46	0.57–3.77	0.43
> 40 years	0.86	0.18–3.23	0.84	2.13	0.57–7.39	0.24	1.17	0.35–3.98	0.80
Sex	0.62	0.16–1.98	0.44	0.40	0.09–1.39	0.18	1.10	0.40–3.03	0.85
SCORAD at baseline									
< 20	5.04	NA–3.10	0.99	5.04	NA–3.10	0.99	5.76	9.17–NA	0.99
20–40	0.26	0.01–1.49	0.21	1.13	0.23–4.41	0.88	3.00	0.79–14.59	0.13
> 40	4.35	0.76–82.33	0.17	1.02	0.27–4.99	0.98	0.28	0.06–1.06	0.08
Introduction dose ≤ 3.5 mg/kg/day	0.09	0.31–2.53	0.85	0.17	0.04–0.57	0.01	2.00	0.81–5.06	0.14
Introduction dose > 3.5–5 mg/kg/day	1.10	0.40–3.19	0.85	<b>5.86</b>	<b>1.74–27.04</b>	<b>0.009</b>	0.50	0.20–1.23	0.14

OR: odds ratio; CI: confidence interval; CsA: cyclosporine A; SCORAD: SCORing Atopic Dermatitis.